Back to top

LACOG 0121 – PET-PSMA

  /    /  LACOG 0121 – PET-PSMA

Retrospective analysis of 68Ga-PSMA-PET in patients with prostate cancer: experience from Brazil (LACOG pPR015)

Type of Study: Epidemiological

Sponsor / Support: LACOG

Primary Objectives: The LACOG 0121 study will describe the rate of patients with 68Ga-PSMA-PET positive lesions [defined as the presence of lesions with 68Ga-PSMA uptake in the prostate (biochemical recurrence) and/or in extra-prostatic sites (localized disease and biochemical recurrence) in patients with no detected lesions in conventional imaging].

Design: This is an observational, retrospective study of patients with diagnosis of prostate cancer with no detection of extra-prostatic disease in traditional imaging who underwent 68Ga-PSMA-PET imaging in localized disease and biochemical recurrence during October 2015 and January 2021.

Sample Size: 700 patients

Principal Investigator: Andrey Soares

Countries LATAM: Brazil

Clinicaltrials.gov Identifier: NCT05169372

The study is open to patients participation in the following research sites:

CPO-RS - Centro de Pesquisa em Oncologia / Porto Alegre / RS / Brazil

ICTR-PR - Instituto do Câncer e Transplante de Curitiba / PR / Brazil

Oncocentro Ceará - Fortaleza / CE / Brazil

Hospital Israelita Albert Einstein / São Paulo / SP / Brazil

HMV-RS - Hospital Moinhos de Vento / Porto Alegre / RS / Brazil

Oncoclínicas-RJ / Rio de Janeiro / RJ / Brazil

Instituto COI / Rio de Janeiro / RJ / Brazil